Starpharma Holdings Limited (AU:SPL) has released an update.
Starpharma Holdings Limited is making significant progress in developing clinical pathways for its lead candidates, DEP® SN38 and DEP® cabazitaxel, as it continues to explore commercialization opportunities. The company is advancing its DEP® HER2 radiodiagnostic program and evaluating collaboration prospects, supported by a strong cash position of $24 million. Key initiatives also include expanding revenue from VivaGel® BV and Viraleze™, despite withdrawing the SPL7013 Nasal Spray application in Australia to focus on higher-priority programs.
For further insights into AU:SPL stock, check out TipRanks’ Stock Analysis page.
